Evidence map›Paper›PMID 41238984›Full record

ArticleAnnals of surgical oncology2026

Prognostic Value of Circulating Tumor DNA for Recurrence and Survival in Patients Undergoing Local Treatment for Initially Unresectable RAS/RAF Mutated Colorectal Cancer Liver Metastases.

Marinde J G Bond, Karen Bolhuis, Theodora C Linders, Clinton Mijnals, Daan van den Broek, Anne M May, Remond J A Fijneman, Cornelis J A Punt, Rutger-Jan Swijnenburg

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marinde J G BondJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. M.J.G.Bond@umcutrecht.nl.ORCID http://orcid.org/0000-0003-0225-5456
Karen BolhuisDepartment of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Theodora C LindersDepartment of Laboratory Medicine, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Clinton MijnalsDepartment of Pathology, OLVG, Amsterdam, The Netherlands.
Daan van den BroekDepartment of Laboratory Medicine, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Anne M MayJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Remond J A FijnemanDepartment of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Cornelis J A Punt *Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Rutger-Jan Swijnenburg *Department of Surgery, Amsterdam UMC, Location University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Funding

KWF Kankerbestrijding 10438
6 · The paper itself

Abstract

backgroundEarly recurrence within 6 months after surgery or ablation of initially unresectable colorectal cancer liver-only metastases (CRLM) occurs frequently and cannot be predicted by currently available clinical and pathological characteristics. This study evaluates the prognostic value of detectable circulating tumor DNA (ctDNA) before liver surgery in patients with initially unresectable CRLM. PATIENTS AND

methodsPatients with KRAS/NRAS/BRAF mutated tumors who underwent R0/R1 resection or ablation of all CRLM after induction systemic treatment were selected from the phase 3 CAIRO5 study. CtDNA was analyzed by droplet digital polymerase chain reaction (PCR) using blood samples collected before starting systemic treatment, before and after local liver treatment.

resultsBaseline and preoperative ctDNA was analyzed in 78 patients. CtDNA was detectable at baseline in 74/78 (95%) patients and preoperatively in 18/74 (24%) patients. Preoperative ctDNA was associated with early recurrence (odds ratio [OR] 3.06, 95% CI 1.04-9.56, p = 0.046), early recurrence without salvage local treatment options (OR 4.30, 95% CI 1.43-13.72, p = 0.011), and overall survival (hazard ratio 2.19, 95% CI 1.22-3.91, p = 0.007). DISCUSSION: Preoperative ctDNA is prognostic for early recurrence and overall survival after local liver treatment in patients with initially unresectable CRLM and KRAS/NRAS/BRAF mutated primary tumors. Further research should determine how to incorporate this parameter into clinical risk scores and therapy management.

Indexed as

Biomarkers, TumorCirculating Tumor DNAColorectal NeoplasmsLiver NeoplasmsMutationNeoplasm Recurrence, LocalProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)AgedFemaleFollow-Up StudiesGTP PhosphohydrolasesHepatectomyHumansMaleMembrane ProteinsBiomarkers, TumorBRAF protein, humanCirculating Tumor DNAGTP PhosphohydrolasesKRAS protein, humanMembrane ProteinsNRAS protein, humanProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)

Identifiers

PMID41238984

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.